Dec 18 (Reuters) - Mirum Pharmaceuticals said on Monday its experimental adjuvant therapy to treat a type of liver disease did not meet main goal in mid-stage study. (Reporting by Khushi Mandowara in Bengaluru; Editing by Maju Samuel)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.37 USD | +0.28% | +2.02% | -14.30% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.30% | 1.19B | |
+41.50% | 54.04B | |
+43.57% | 41.96B | |
-1.26% | 41.92B | |
-7.59% | 28.35B | |
+12.19% | 26.35B | |
-22.48% | 19B | |
+7.83% | 13B | |
+29.08% | 12.28B | |
+24.94% | 12.19B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharma's liver disease therapy fails in mid-stage study